0000000001179956

AUTHOR

T. Patrizia

showing 3 related works from this author

Mortality rate and risk factors for gastrointestinal bleeding in elderly patients

2019

Abstract Background Gastrointestinal bleeding (GIB) is burdened by high mortality rate that increases with aging. Elderly patients may be exposed to multiple risk factors for GIB. We aimed at defining the impact of GIB in elderly patients. Methods Since 2008, samples of elderly patients (age ≥ 65 years) with multimorbidity admitted to 101 internal medicine wards across Italy have been prospectively enrolled and followed-up (REPOSI registry). Diagnoses of GIB, length of stay (LOS), mortality rate, and possible risk factors, including drugs, index of comorbidity (Cumulative Illness Rating Scale [CIRS]), polypharmacy, and chronic diseases were assessed. Adjusted multivariate logistic regressio…

RegistrieMaleSettore MED/09 - Medicina Interna030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk Factors80 and over030212 general & internal medicineHospital MortalityProspective StudiesRegistriesProspective cohort studyMultivariate AnalysiAged 80 and overDiverticulosisMortality rateDiverticulosiGastric ulcerAnemiaAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Internal MedicineItalyPlatelet aggregation inhibitorFemaleGastrointestinal HemorrhageAntiplatelet drugHumanGastrointestinal bleedingmedicine.medical_specialtyLogistic ModelAnemiaSocio-culturaleAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity03 medical and health sciencesInternal medicineSeverity of illnessInternal MedicinemedicineHumansAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Aged; Aged 80 and over; Female; Gastrointestinal Hemorrhage; Hospital Mortality; Humans; Italy; Length of Stay; Logistic Models; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Factors; Severity of Illness Index; MultimorbidityAgedPolypharmacybusiness.industryPlatelet Aggregation InhibitorRisk FactorAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; MultimorbidityAnticoagulantMultimorbidityAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity Aged Aged 80 and over Female Gastrointestinal Hemorrhage Hospital Mortality Humans Italy Length of Stay Logistic Models Male Multivariate Analysis Platelet Aggregation Inhibitors Prospective Studies Registries Risk Factors Severity of Illness Index MultimorbidityLength of Staymedicine.diseaseComorbidityProspective StudieLogistic ModelsMultivariate AnalysisbusinessPlatelet Aggregation Inhibitors
researchProduct

Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study

2019

<b><i>Objective:</i></b> Older people approaching the end of life are at a high risk for adverse drug reactions. Approaching the end of life should change the therapeutic aims, triggering a reduction in the number of drugs.<b><i></i></b>The main aim of this study is to describe the preventive and symptomatic drug treatments prescribed to patients discharged with a limited life expectancy from internal medicine and geriatric wards. The secondary aim was to describe the potentially severe drug-drug interactions (DDI). <b><i>Materials and Methods:</i></b> We analyzed Registry of Polytherapies Societa Italiana di Medicina I…

0301 basic medicineDrugMalemedicine.medical_specialtyDeprescriptions020205 medical informaticsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medications; Aged 80 and over; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Male; Polypharmacy; Deprescriptions; Life Expectancy; Patient DischargeSocio-culturale02 engineering and technology03 medical and health sciencesElderly · End of life · Limited life expectancy · Polypharmacy · Symptomatic medicationsPharmacotherapyDeprescriptionsLife ExpectancyElderlySymptomatic medications0202 electrical engineering electronic engineering information engineeringmedicine80 and overHumansLS4_4Medical prescriptionElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medicationsmedia_commonAgedPolypharmacyAged 80 and overOriginal Paperbusiness.industryGeneral MedicineElderly End-of-life Limited life expectancy Polypharmacy Preventing medications Symptomatic medicationsElderly End of life Limited life expectancy Polypharmacy Symptomatic medicationsPatient DischargeClonidineLimited life expectancyItalyEmergency medicineEnd of lifeLife expectancyPolypharmacyFemale030101 anatomy & morphologyDeprescribingbusinessmedicine.drugSymptomatic medication
researchProduct

Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial…

2022

: Background A significant proportion of individuals clinically diagnosed with familial hypercholesterolemia (FH), but without any disease-causing mutation, are likely to have polygenic hypercholesterolemia. We evaluated the distribution of a polygenic risk score, consisting of 12 low-density lipoprotein cholesterol (LDL-C)-raising variants (polygenic LDL-C risk score), in subjects with a clinical diagnosis of FH. Methods and Results Within the Lipid Transport Disorders Italian Genetic Network (LIPIGEN) study, 875 patients who were FH-mutation positive (women, 54.75%; mean age, 42.47±15.00 years) and 644 patients who were FH-mutation negative (women, 54.21%; mean age, 49.73±13.54 years) wer…

MaleAdultMultifactorial InheritanceSettore MED/09 - Medicina Internafamilial hypercholesterolemia; molecular diagnosis; polygenic risk score; Adult; Cholesterol LDL; Female; Humans; Middle Aged; Multifactorial Inheritance; Mutation; Gene Regulatory Networks; Hyperlipoproteinemia Type IIfamilial hypercholesterolemiaCholesterol LDLMiddle AgedLDLHyperlipoproteinemia Type IICholesterolmolecular diagnosispolygenic risk scoreMutationHumansFemaleGene Regulatory Networksmolecular diagnosifamilial hypercholesterolemia; molecular diagnosis; polygenic risk score
researchProduct